Abstract
International Journal of Medicine and Public Health,2022,12,3,96.DOI:10.5530/ijmedph.2022.3.19Published:August 2022Type:Guest EditorialPROTACs: Opportunities and Challenges Ahead in the Field of Drug DiscoveryAnish Kizhakkekkara Vadukoot Anish Kizhakkekkara Vadukoot Department of Biochemistry, School of Medicine, Vanderbilt University 2123 Garland Ave, MRB IV 12445, Nashville, TN , USA Abstract:Proteolysis Targeting Chimeras (PROTACs) are alternatives to traditional small molecule-based drug discovery techniques that focus on direct regulation of protein activity. Targeted protein degradation in cells by heterobifunctional small molecules has emerged as one of the most promising technologies for modulating a protein of interest (POI). PROTACs connect three chemical elements: POI ligand to an E3 ubiquitin ligase (E3) recruiting ligand with an optimal linker for conjugating these two ligands.1 PROTACs cause degradation via the ubiquitinproteasome system (UPS) through proximityinduced ubiquitination of the POI. PROTACs induce target protein degradation at low exposures due to their catalytic mode of action thus making them an attractive platform for cancer therapy and other diseases. Read more.... View:PDF (64.01 KB)
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
